Oncology clinical trials appeared to recover from declines in enrollment and activation during the early phase of the COVID-19 pandemic, according to a study of data from two large academic centers published in Annals of Oncology.
Researchers found academically sponsored trials experienced more prominent declines than industry-sponsored trials, and they observed racial disparities among patients taken off clinical trials.
“Clinical trials are resource-intensive endeavors that are particularly susceptible to disruption by the pandemic, but are crucial to advancing cancer care,”